explore -WSS

explore

author：explore 2025-09-30 20:20:01 - browse：6611

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Pandemic and All Hazards Preparedness Act needs lean update

entertainment

WSS

How a Boston hospital is priming medical residents to use GPT

Giraffe named Twiga, who was among the oldest cared for by humans, died at age 31 at East Texas zoo

Parents surprise family after baby discharged from NICU after 170 days

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

The aspartame in Diet Coke probably isn’t giving you cancer

focus

explore

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Biden’s NIH nominee is languishing in Congress

Cancer drug shortages should be causing more outrage

Judge agrees to delay next hearing in Trump classified documents case

Medical leaders decry Supreme Court decision on affirmative action

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Tori Bowie and the unacceptable rates of Black maternal death

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

knowledge

Teachers share how revamped forgiveness program helped with their student loans

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Stanford president’s abrupt resignation sparks debate

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

'CMA Fest' 2023: How to watch, who is performing and more

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

hotspot

entertainment

hotspot

knowledge